Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1.1 Million Shares

Director Ali Behbahani acquired options to purchase 1,144,686 ordinary shares of Adaptimmune Therapeutics PLC on July 1, 2024, at an exercise price of $0.16 per share.

Summary

• On July 1, 2024, Ali Behbahani, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 1,144,686 ordinary shares.
• The exercise price for these options is $0.16 per share, converted from GBP0.13 based on an exchange rate of U.S.$1.263714 to GBP1.00.
• The options become exercisable on July 1, 2025, and expire on July 1, 2034.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of an insider transaction. The acquisition of options by a director can be seen as a mildly positive signal, but it's not a strong indicator of future performance.

Positives

• A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This transaction is a routine disclosure of insider activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates